Luspatercept for non-deletional hemoglobin H disease.
Yang YN, Chou YY, Cheng CN.
Pediatr Blood Cancer. 2024 Oct;71(10):e31224. doi: 10.1002/pbc.31224. Epub 2024 Jul 23.
Hemoglobin H disease: not necessarily a benign disorder.
Chui DH, Fucharoen S, Chan V.
Blood. 2003 Feb 1;101(3):791-800. doi: 10.1182/blood-2002-07-1975. Epub 2002 Sep 12.
Alpha and beta thalassemia.
Muncie HL Jr, Campbell J.
Am Fam Physician. 2009 Aug 15;80(4):339-44.
Detection of hemoglobin H disease by long molecule sequencing.
Li Y, Liang L, Qin T, Tian M.
J Clin Lab Anal. 2022 Oct;36(10):e24687. doi: 10.1002/jcla.24687. Epub 2022 Sep 4.
Disease burden, management strategies, and unmet needs in alpha-thalassemia due to hemoglobin H disease.
Lal A, Viprakasit V, Vichinsky E, Lai Y, Lu MY, Kattamis A.
Am J Hematol. 2024 Nov;99(11):2164-2177. doi: 10.1002/ajh.27440. Epub 2024 Jul 22.
Clinical Classification, Screening and Diagnosis for Thalassemia.
Viprakasit V, Ekwattanakit S.
Hematol Oncol Clin North Am. 2018 Apr;32(2):193-211. doi: 10.1016/j.hoc.2017.11.006.
Weighing the evidence for newborn screening for Hemoglobin H disease.
Kemper AR, Knapp AA, Metterville DR, Comeau AM, Green NS, Perrin JM.
J Pediatr. 2011 May;158(5):780-3. doi: 10.1016/j.jpeds.2010.10.042. Epub 2010 Dec 16.
The α-thalassemias.
Piel FB, Weatherall DJ.
N Engl J Med. 2014 Nov 13;371(20):1908-16. doi: 10.1056/NEJMra1404415.
Hemoglobin H disease.
JIM RT.
AMA Arch Intern Med. 1958 Sep;102(3):400-4. doi: 10.1001/archinte.1958.00030010400008.
Leveraging Multi-Omics Approaches and Advanced Technologies to Unravel the Molecular Complexities, Modifiers, and Precision Medicine Strategies for Hemoglobin H Disease.
Pahelkar A, Sharma D, Vohra P, Sawant S.
Eur J Haematol. 2024 Dec;113(6):738-744. doi: 10.1111/ejh.14319. Epub 2024 Oct 9.
